

Dr. Diane Heiser, PhD, is the Vice President of Translational Research & Hematology at Prelude Therapeutics – a clinical-stage biotechnology company developing precision therapeutics to target key drivers of cancer growth and resistance. At Prelude, Diane leads precision medicine and translational research efforts across clinical and preclinical stage programs.

Before joining Prelude, Diane was a co-founder of Notable Labs, where she served as Chief Scientific Officer and Chief Technology Officer. Diane led Notable through successful seed, Series A and Series B funding rounds, building the scientific team and creating a high-throughput fully automated personalized medicine platform for patients with blood cancers. Passionate about leveraging novel technologies for translational research, Diane has served as an advisor for many early-stage Techbio companies, helping to build and scale technology platforms and scientific teams. She serves as a mentor for key leaders at biotechnology startups transitioning to management or new strategic roles, with a particular focus on women and underrepresented minorities.

Diane obtained her BA in Molecular Biology from Princeton University followed by a PhD in Cellular & Molecular Medicine from Johns Hopkins School of Medicine and a postdoctoral scholarship at Stanford University.